Breast Cancer Liquid Biopsy Market Anticipated to Reach $2.73 Billion by 2034, Growing at an 8.5% CAGR

The breast cancer liquid biopsy market size was valued at USD 1,209.01 million in 2024. It is projected to grow to USD 2,731.02 million by 2034, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2025 to 2034.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧:
Breast cancer liquid biopsy is a less invasive option utilizing blood as a sample and is preferred over a surgical tissue biopsy. Different biomarkers like circulating tumor cells (CTC), extracellular vesicles, and circulating tumor DNA are employed in the identification of breast cancer. Liquid biopsy for breast cancer helps in tracking the advancement of the disease by analyzing the diversity of tumor cells in late-stage breast cancer.

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market/request-for-sample

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:
• The growth of the breast cancer liquid biopsy market is driven by technological advancements like molecular biology innovations, next-generation sequencing (NGS), and advanced ctDNA detection technologies.
• The rising number of breast cancer cases around the world, particularly in developed areas, creates a greater demand for non-invasive methods of diagnosis like liquid biopsy to detect and monitor the disease early.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
Because there are so many companies in the market, it is expected to be both competitive and fragmented.
Here is the list of the leading companies operating in the breast cancer liquid biopsy market:
• Biocept, Inc.
• Epic Sciences, Inc.
• F. Hoffmann - La Roche Ltd.
• Fluxion Biosciences, Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• QIAGEN
• Sysmex Corporation
• The Menarini Group
• Thermo Fisher Scientific, Inc.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market/request-for-discount-pricing

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The market is mainly segmented based on the application, circulating biomarkers, and region. Based on circulating biomarkers analysis, the circulating cell-free DNA (cfDNA) segment held the largest market share in 2024 because it is more sensitive and specific in identifying different forms of cancers, such as breast cancer. Cell-free DNA consists of tiny DNA fragments that dying cells release into the bloodstream, providing valuable insights into a tumor's genetics and behavior.
Moreover, according to the application analysis, during the projection period, the early detection/screening segment is anticipated to register the highest CAGR due to the growing understanding of the significance of detecting cancer early in order to enhance patient outcomes.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market/inquire-before-buying

𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬
• Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.
• The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.
• In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.
• The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.
• A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭:
𝐍𝐞𝐞𝐝𝐥𝐞 𝐇𝐨𝐥𝐝𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/needle-holder-market

𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market

𝐆𝐋𝐏-𝟏 𝐀𝐧𝐚𝐥𝐨𝐠𝐮𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/glp-1-analogues-market

𝐈𝐧 𝐕𝐢𝐭𝐫𝐨 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐂𝐨𝐧𝐭𝐫𝐨𝐥 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/in-vitro-diagnostics-quality-control-market

𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
https://www.polarismarketresearch.com/industry-analysis/spatial-proteomics-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.